Page last updated: 2024-12-09

(2-bromophenyl)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(2-Bromophenyl)thiourea is a **chemical compound** that is often used in research due to its interesting properties and applications.

Here's a breakdown:

**What it is:**

* **Structure:** It's composed of a thiourea group (NH2-C(=S)-NH2) attached to a phenyl ring (a six-membered carbon ring with alternating single and double bonds) with a bromine atom at the 2-position (meaning it's attached to the carbon atom next to the point where the thiourea group is attached).
* **Appearance:** It's typically a white to off-white solid.

**Why it's important for research:**

(2-Bromophenyl)thiourea has been used in a variety of research areas, primarily due to its:

* **Biological activity:** It has shown **antimicrobial**, **antifungal**, and **anti-inflammatory** properties. This makes it potentially useful for developing new medicines and therapies.
* **Ligand properties:** It can act as a **ligand**, a molecule that binds to a metal ion or another molecule. This property is crucial for studying metal complexes and their potential applications in catalysis, materials science, and bioinorganic chemistry.
* **Crystallization properties:** It can form **crystals** with unique properties, which makes it suitable for studying crystal growth and solid-state physics.
* **Synthetic intermediate:** It can be used as a starting material for synthesizing other compounds with desired properties.

**Specific research areas where it's used:**

* **Medicinal chemistry:** Researching its potential as a new drug candidate for various diseases.
* **Coordination chemistry:** Studying the formation and properties of metal complexes with (2-bromophenyl)thiourea.
* **Materials science:** Exploring its potential use in developing new materials with specific properties.
* **Organic synthesis:** Investigating its use as a building block in the synthesis of other organic molecules.

**It's important to note:**

* The research on (2-bromophenyl)thiourea is ongoing, and its full potential is still being explored.
* Safety precautions must be taken when handling this compound, as it can be harmful if ingested or inhaled.

In summary, (2-bromophenyl)thiourea is a versatile compound that has sparked research interest in various fields due to its unique chemical properties and potential applications in medicine, materials science, and organic synthesis.

Cross-References

ID SourceID
PubMed CID2735618
CHEMBL ID1534587
CHEBI ID120635
SCHEMBL ID2357864
SCHEMBL ID11693811

Synonyms (33)

Synonym
thiourea, (2-bromophenyl)-
thiourea,(2-bromophenyl)-
1-(2-bromophenyl)-2-thiourea
n-(2-bromophenyl)thiourea
MLS000835024
smr000461640
CHEBI:120635
(2-bromophenyl)thiourea
EN300-87357
NCGC00246708-01
1-(2-bromophenyl)thiourea
A829826
2-bromophenylthiourea
5391-30-0
AKOS005202770
HMS2794J18
FT-0611599
QIGMVYSPXPXCPN-UHFFFAOYSA-N
2-bromophenyl thiourea
SCHEMBL2357864
SCHEMBL11693811
|a-tosyl-(2,3-difluorobenzyl)isocyanide
thiourea, (bromophenyl)-
CHEMBL1534587
Q27208765
DTXSID80202186
mfcd00041146
CCG-256086
o-bromophenylthiourea
STL510539
F19866
CS-16214
CS-0093548
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thioureasCompounds of general formula RR'NC(=S)NR''R'''.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency100.00005.623417.292931.6228AID485281
TDP1 proteinHomo sapiens (human)Potency11.58210.000811.382244.6684AID686978
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency22.19690.00798.23321,122.0200AID2546; AID2551
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency0.10000.075215.225339.8107AID485360
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency7.07950.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]